ImmunoBrain Checkpoint's antibody that boosts immune cells' communication with brain seen effective in lab animals; clinical trials in humans to start next year

Drug developed by Jerusalem-based startup targets cancer cells, weakens their defenses, and activates a local response, company says; Swiss pharma firm Roche to join trials

Weizmann Institute researchers find the more cancer cells differ from one another, the less effective immunotherapies are; they hope ultimately to create personalized treatments